Doctors learn more about diagnosing rare form of cancer

April 24, 2006

WINSTON-SALEM, N.C. - Their experience treating a rare type of abdominal cancer has helped physicians at Wake Forest University Baptist Medical Center make a new discovery that may change the way it is diagnosed. The results are reported in the May issue of the American Journal of Surgical Pathology.

"Our study suggests that tumors of the appendix that have spread through the abdominal cavity all qualify as cancer," said Robert F. Bradley, M.D., principal investigator. "Previously, some of the tumors were classified as 'benign,' which we believe gives a false sense of how the tumor will behave."

Bradley, a pathology resident, and colleagues focused on 101 patients with pseudomyxoma peritonei, a rare form of cancer of the lining of the abdominal cavity. The cancer, which produces mucin, a "jelly-like" substance, usually originates in the appendix or colon and spreads to the abdominal lining. Bradley evaluated all available microscopic slides in cases proven to come from the appendix.

Wake Forest is one of a few centers in the country that offer a combined treatment - surgery to remove the tumor and then infusion of heated chemotherapy drugs into the abdominal cavity. Because it treats patients from all over the country with the disease, Wake Forest had a unique opportunity to clear up confusion about its diagnosis.

"Because it is so rare - less than 0.1 percent of appendices are removed for cancer -- the disease has been plagued with controversy and confusing terminology," said Bradley.

Currently, many pathologists who study sections of the tumor after surgery classify it into three general categories: high-grade cancer, low-grade cancer, and benign. All of the patients normally receive the same treatment - the grade of the tumor indicates how patients will respond.

The investigators from Wake Forest compared the diagnoses made using these three grades with patients' outcome after receiving standardized treatment. Patients in the study, which is the largest to date of pseudomyxoma peritonei that originated from the appendix, were treated from 1993 to 2005.

The researchers found one-year, three-year and five-year survival rates were not significantly different for patients in the "low-grade cancer" and "benign" categories. However, patients in the "high-grade" category had significantly worse survival.

"Hopefully this will help resolve the confusion in diagnosis," said Bradley. "Our study shows that there is no separate 'benign' variant of the disease. Instead, physicians should expect those tumors that look 'benign' microscopically to behave like low-grade cancer. We now combine those cases into one diagnosis of low-grade carcinoma, for which the prognosis should be equally favorable with adequate treatment."

Bradley said the way the disease is diagnosed has implications for how it is viewed and treated.

"We hope this will lead to a more standardized diagnosis so that these patients' doctors understand exactly what it means," he said.

About 66 percent of patients with the low-grade variant who are aggressively treated with surgery and abdominal chemotherapy survive at least five years and are potentially cured, Bradley said. The chemotherapy treatment is known as intraperitoneal hyperthermic chemotherapy (IPHC).

Last year, Wake Forest researchers reported on their experience using the combination of surgery and IPHC for tumors that had spread from the appendix, small bowels and ovaries. They also use the treatment for tumors that have spread from the colon, rectum and stomach.

Surgery alone has been shown to have limited effectiveness, but the combination therapy improves overall survival and quality of life in selected patients. For example, patients whose cancer had spread from the small bowel had a mean survival of almost 4 years with combination therapy, compared to 3.1 months for patients who received only traditional treatment.
Other researchers involved in the study to clarify diagnosis were John Stewart, M.D., Gregory Russell, M.S., Edward Levine, M.D., and Kim Geisinger, M.D., all with Wake Forest Baptist.

Media Contacts: Karen Richardson,, or Shannon Koontz,, 336-716-4587.

Wake Forest University Baptist Medical Center is an academic health system comprised of North Carolina Baptist Hospital and Wake Forest University Health Sciences, which operates the university's School of Medicine. The system comprises 1,187 acute care, psychiatric, rehabilitation and long-term care beds and is consistently ranked as one of "America's Best Hospitals" by U.S. News & World Report.

Wake Forest Baptist Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to